Prevention, Diagnosis & Treatment
Bayer’s brands treat and prevent conditions to improve quality of life.
October 24, 2018
Phase III Trial of Darolutamide in Patients with Non-metastatic Castration-resistant Prostate Cancer Meets Primary Endpoint
The Phase III ARAMIS (Androgen Receptor inhibiting Agent for MetastatIc-free Survival) trial that investigated darolutamide in men with non-metastatic castration-resistant prostate cancer...
October 21, 2018
Larotrectinib Delivers 81% Overall Response Rate in an Expanded Dataset of 109 TRK Fusion Cancer Patients Across Ages and Tumor Types
Bayer and Loxo Oncology, Inc. (Nasdaq: LOXO), today announced updated clinical data for larotrectinib in adult and pediatric patients with TRK fusion cancer across 24 unique tumor types. The...
October 09, 2018
Bayer to Showcase Latest Oncology Research at ESMO 2018 Congress
Bayer will present new data from the company's growing oncology portfolio at the ESMO 2018 Congress (European Society for Medical Oncology) taking place October 19-23 in Munich, Germany. Among the...
Last Updated: September 19, 2018